|
Centocor paid $335 million for Retavase. Would anyone care to share what the other firms who were interested in Retavase bid for the product? part 2 of this Q&A would discuss the differences in bidding among the interested parties. Regarding Remicade, the patient is required to schlepp (a medical term) to a place to get it. Immunex's Enbrel does not require the schlepp. But, how can someone with RA inject themselves? If the product did not help, it would be tough - but since it helps, they can and they will. However, two days before Halloween, the gastroenterology and urology committee within the device division of our FDA will evaluate a product with little if any side effects, meaning it could be used in combination with drugs, but of course, depending on the patient, and statistically speaking, there will be some RA patients for whom the product alone, will be just fine. Confounding the situation is the issue of managed care, since using our Haloween product in combination with drug therapy means paying for two treatments. Funny that no sell side analyst eps model for Centocor even considers this. The Haloween product would not be a factor until 1999, which to somebody writing a research report for a brokerage firm needing underwritings in a market where brokerage firms teeter on the edge of going under, is a time horizon that is irrelevant, but only in leaving out potential negatives. wonder why? - could it be that CNTO overpaid by a factor of 4 for Retavase, and they have investment banking services needed? Disney was a must own stock, and Centocor, as one of few large cap biotechs is a stock pm's who don't know a cell from a sell would buy for biotech exposure. Maybe I just don't like mice. (hidden message, like a fortune cookie) |
